focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
It finished 24.62.
Hear hear
Cheers Tommy.
Yes, different SOC across the many countries may have been just one reason why endpoints weren’t met.
Not read it all yet, but great post.
ATB
Just saying.
Manifesto
Yes, that may hopefully be the case.
I have asked the same question from our Head of Comms, but have received nothing.
I thought I had missed something!
ATB
Tommy
Can you show me where the company have said that, post Sprinter readout?
Will Synairgen apply for EUA, if data is combined and also if it unearths some key positives from the deep dive analysis? Is this a direct question for our Head of Comms?
Does she have a part time role now, because I would love to know what her job description entails and how she fills her time?
Thanks folks for this update.
I’m sure RM is aware of this, then again :)
‘And before you ask - yes I am an investor in this share.’
So, you’re not invested, hence my previous comment.
Elsol
£2.50ish at this point would be very nice.
Yes, pls.
:)
Thankyou.
ATB to you also!
Let’s hope we have a few months of positivity to look forward to.
Peace and prosperity to all, including SNG LTH’s.
Yes, agreed manifesto.
Another moby.
Oj
I feel sorry for anyone that lies on a public forum.
‘i might buy back in at 10p but as i mentioned about 10 days ago this company will run out of money’
Why don’t you buy Evraz- is that what it’s callled?
Keep smiling, it’s only money.
Tommy
Agreed, this is key.
Let’s hope our CEO is up-to-speed.
TL
We have very much the same philosophy.
Covid symptoms more or less abated for me, although I’m still testing positive.
Partner has recovered after full quota of antibiotics, albeit still a little chesty.
Many thanks for your comments.
ATB.
TL
I can imagine you’re frustrated, same here. I think the fully unblinded data might just unearth some statistically positive data; if not, we will wonder even more how the trial has been so poorly designed whilst working with a supposed expert in trial design, etc - hopefully, not a discussion for later.
A key focus may be the impact on long covid, as this is clearly a concern for many people across many countries.
We certainly hope that the company is working hard to restore commercial viability to SNG001. We hope they are planning to amalgamate all available date (if that’s possible) but the problem for me is they haven’t communicated that this is their plan. The only plan is a platform trial, which will take lots of time and money. Where is the evidence, following two failed trials already that this is worthwhile pursuing?
If we end up applying for EUA from the whole data sets, then I would guess the SP could return to pre-RNS levels.
My preference too would be for a successful takeover bid as Synairgen have shown that they can’t work at the required pace. As you say, they have failed to demonstrate their proposed endpoints in two successive trials and there is nothing to suggest that they have the capability to take their product further, if you judge on past performance.
We will wait, again.
At least we know that A2 data will be in before June, let’s hope Sprinter deep dive does it before then!!
ATB TL
Preferably, not at the same time as a steroid.
:)
Thanks Titania.
I might have a read later.
ATB
Aether
No offence meant - pls accept my apology.
There is no quick fix with this imo.
If a miracle happens and we go for EUA, it’ll take RM months to put it together by which time we have another variant that excludes us. Sorry, could t resist :)
I’m sure Poly have a plan, otherwise why keep buying?
I’m sure there are many companies that have been bought out, on the cheap, following poor results.
This is a waiting game, again!
Aether
That is a ridiculous question.
How can anyone answer that with any accuracy.
Do you want a guess?